BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.4M Compounds and 9.6K Targets. Of those, 1.5M data for 718K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

21 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells.EBI
University of Tennessee Health Science Center
Discovery of ONO-7300243 from a Novel Class of Lysophosphatidic Acid Receptor 1 Antagonists: From Hit to Lead.EBI
Ono Pharmaceutical
Discovery of novel S1P2 antagonists. Part 1: discovery of 1,3-bis(aryloxy)benzene derivatives.EBI
Ono Pharmaceutical
Design and synthesis of sulfamoyl benzoic acid analogues with subnanomolar agonist activity specific to the LPA2 receptor.EBI
The University of Tennessee Health Science Center
Phosphorothioate analogs of sn-2 radyl lysophosphatidic acid (LPA): metabolically stabilized LPA receptor agonists.EBI
The University of Utah
Selective non-lipid modulator of LPA5 activity in human platelets.EBI
Sanofi-Aventis Deutschland
Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents.EBI
Amgen
Synthesis and SAR studies of a novel class of S1P1 receptor antagonists.EBI
Sankyo
Structure-based drug design identifies novel LPA3 antagonists.EBI
The University of Memphis
Identification of non-lipid LPA3 antagonists by virtual screening.EBI
The University of Memphis
Lysophosphatidic acid (LPA) receptor modulators: Structural features and recent development.EBI
Jss Academy of Higher Education and Research
Phosphonothioate and fluoromethylene phosphonate analogues of cyclic phosphatidic acid: Novel antagonists of lysophosphatidic acid receptors.EBI
The University of Utah
Identification of Darmstoff analogs as selective agonists and antagonists of lysophosphatidic acid receptors.EBI
University of Tennessee Health Science Center
Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands.EBI
University of Tennessee Health Science Center
Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin.EBI
University of Tennessee Health Science Center
Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPAEBI
Universidad Complutense De Madrid
Selecting against S1P3 enhances the acute cardiovascular tolerability of 3-(N-benzyl)aminopropylphosphonic acid S1P receptor agonists.EBI
Merck Research Laboratories
Synthesis and biological evaluation of phosphonic and thiophosphoric acid derivatives of lysophosphatidic acid.EBI
Oxford University
Discovery of Potent Selective Nonzinc Binding Autotaxin Inhibitor BIO-32546.EBI
Biogen
Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry.EBI
X-Chem
A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPAEBI
Universidad Complutense De Madrid